---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-026135"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T09:51:02.419260+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Protagonist transitions rusfertide NDA regulatory leadership to Takeda

## Summary
- Takeda to lead regulatory strategy and NDA preparation for rusfertide in polycythemia vera; transition underway.
- Protagonist remains primarily responsible for clinical development activities through NDA filing.
- Decision made under License and Collaboration Agreement dated January 31, 2024, as amended.

## SEC filing metadata
- accession: 0001104659-25-026135
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465925026135/0001104659-25-026135-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465925026135/tm259835d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-026135
- JSON: https://secwatch.observer/filing/0001104659-25-026135.json
- Plain text: https://secwatch.observer/filing/0001104659-25-026135.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.